

RealRate

PHARMACEUTICAL 2019

Viking Therapeutics Inc. Rank 9 of 363







RealRate

Viking Therapeutics Inc. Rank 9 of 363

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Viking Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 319%, being 282% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	302,133
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,550
Liabilities, Non-Current	12
Other Assets	179
Other Compr. Net Income	-403
Other Expenses	0
Other Liabilities	0
Other Net Income	4,098
Other Revenues	0
Property and Equipment	0
Research and Development	19,040
Selling, General and Administrative Expense	7,121

Output Variable	Value in 1000 USD
Assets	302,312
Liabilities	4,562
Expenses	26,161
Revenues	0
Stockholders Equity	297,750
Net Income	-22,063
Comprehensive Net Income	-22,264
Economic Capital Ratio	319%

